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ethical considerations on the development
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Abstract
Precision medicine promises to develop diagnoses and treatments that take individual variability into account.
According to most specialists, turning this promise into reality will require adapting the established framework of
clinical research ethics, and paying more attention to participants’ attitudes towards sharing genotypic, phenotypic,
lifestyle data and health records, and ultimately to their desire to be engaged as active partners in medical research.
Notions such as participation, engagement and partnership have been introduced in bioethics debates concerning
genetics and large-scale biobanking to broaden the focus of discussion beyond individual choice and individuals’
moral interests. The uptake of those concepts in precision medicine is to be welcomed. However, as data and
medical information from research participants in precision medicine cohorts will be collected on an individual
basis, translating a participatory approach in this emerging area may prove cumbersome. Therefore, drawing on
Joseph Raz’s perfectionism, we propose a principle of respect for autonomous agents that, we reckon, can address
many of the concerns driving recent scholarship on partnership and public participation, while avoiding some of
the limitations these concept have in the context of precision medicine. Our approach offers a normative
clarification to how becoming partners in precision is compatible with retaining autonomy.
Realigning the value of autonomy with ideals of direct engagement, we show, can provide adequate normative
orientation to precision medicine; it can do justice to the idea of moral pluralism by stressing the value of moral
self-determination: and, finally, it can reconcile the notion of autonomy with other more communitarian values
such as participation and solidarity.
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Background
Personalized medicine refers to a family of approaches
in biomedical research and clinical practice aimed at
“steering the patient to the right drug at the right dose
at the right time” [1]. This idea has always enjoyed some
recognition in modern medicine. However, in the last
couple of decades, it almost reached the status of a
distinctive way of thinking about health, disease and
therapy. Since the early days of pharmacogenetics, and
up until the announcement of the Precision Medicine
Initiative (PMI) in January 2015, this emerging paradigm
has been promising nothing less than a revolution in
medicine. However, precision medicine does not only
promise to change our understanding of disease and the
way health care is delivered to patients. It also contains
an element of novelty with respect to how research
participants and patients involved in its clinical develop-
ment should be considered, what they should be entitled
to, and how they should be treated as they get associated
with the enterprise of precision medicine. In particular,
the emergence of precision medicine is accompanied by
a demand for a participatory understanding of the role
of patients and research participants as “active partners
in clinical research” [2].
Interestingly, this language is not entirely new. In
the early Fifties, at the Clinical Center of the National
Institutes of Health’s, intramural research had to com-
ply with a set of ethical principles (remarkably advanced
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for that period) that defined research participants as part-
ners in research [3]. Thirty years later, in a 1984 paper,
Daniel Callahan recognized that the raise of bioethics had
“brought patients into a full partnership with physicians in
their medical care” ([4], added emphasis).1
Despite such appearances, however, the notion of part-
nership has not enjoyed much consideration in main-
stream bioethics until relatively recent times. In truth,
this notion is often presented as a way to cope with the
shortcomings stemming from “the paramount position
of the individual in ethics” [5]. Based on this intuition,
many in bioethics started to emphasize the importance
of a broader set of normative concerns having to do with
considering research subjects as partners who should be
given ways to participate in the governance of research.
Similar appeals to partnership, participation and engage-
ment2 characterize the normative framing of precision
medicine by the leadership of the Precision Medicine
Initiative.
Launched in January 2015 by President Barack Obama,
the Precision Medicine Initiative revolves around the cre-
ation of a large national cohort (run by the National Insti-
tutes of Health) of at least one million individuals who will
contribute extensive amounts of medical, genetic, genomic,
behavioral, phenotypic and biomarkers data, as well as life-
style and other personal information. Research participants
will continue to contribute data over the years, thus enabling
researchers to look for medically relevant correlations based
on an ever-growing longitudinal cohort. Thanks to rapid
progress in data science, machine learning and big data ana-
lytics, the precision medicine cohort is expected to usher in
a new era of biomedical research – thus leading to new
“prevention and treatment strategies that take individual
variability into account” [2]. Precision medicine is premised
on the idea that the “patient is an enormous repository of
information that needs to be harvested as a partnership not
only in clinical care but in discovery [as a way to] define
wellness and its progression to disease, rather than trad-
itional medicine that defines disease and its progression to
death” [6]. If the promise of precision medicine will
materialize, there will be considerable improvements in un-
derstanding disease risk, individual predispositions, as well
as the contribution of the environment and lifestyle to dis-
ease onset and to the way individuals respond to therapy.
This is expected to result in a considerably increased cap-
acity to tailor treatment and prevention strategies to the
needs and characteristics of individuals – thus improving
treatment outcomes and making health care systems more
efficient and more sustainable.3
Interestingly, for the establishment of the precision
medicine cohort, the PMI explicitly embraces ideals of
participation and partnership, as it sets out to capitalize
on “Americans’ growing desire to be active partners in
modern science” [2].
Discussion
The normative construction of research partners
In research ethics, concepts such as partnership and
participation designate a procedural ideal of direct en-
gagement of research subjects in the organization and
implementation of studies in which they are enrolled.
Interestingly, the ethical values that underpin this ideal
are often constructed to supplement the centrality of in-
dividual moral interests that, since the late Seventies,
has been characteristic of clinical research ethics and
medical ethics.
Such novel normative orientation gradually emerged in
the Nineties, in concomitance with the growth of large-
scale research biorepositories (commonly known as bio-
banks). More recently, technical progress in genome se-
quencing gave further impetus to both research and large-
scale biobanking initiatives – such as the constitutions of
national biological repositories [7]. This type of biological
collection, many argued, pose novel ethical challenges. In
particular, it has been argued that biobanking promoted a
shift in focus from individuals to groups. What these
repositories typically collect is biological material from
genetically isolated populations, populations bearing med-
ically favorable traits (like longevity or reduced incidence
of a given disease), minorities, families in which a given
disease shows up with increased frequency, groups of
people affected by the same conditions or sharing a com-
mon genetic mutation, and patients affected by a rare or
orphan disease. As a consequence, in that period, bio-
ethical debates started to consider novel issues, such as the
rights and interests of those who contribute biological
material to research as members of a particular group.
For instance, when culturally sensible issues are at
stake, collective forms of authorization (or group con-
sent) can serve morally relevant interests that it would
otherwise be hard to take into account [8]. Moved by
similar concerns, some have also observed that “Ameri-
can bioethics has been dominated by the goal of individ-
ual control” (epitomized by the emphasis on individual
consent), and that forms of deliberative engagement in
the governance of large scale genomics research may
broaden the scope of discussion in favorable ways [9].
This focus on collectivities is also visible in discussions
about returning research benefits to the community that
contributed tissue and information, and thus made re-
search possible in the first place. This entails soliciting
communities of research participants to express their
views and expectations concerning a given study, taking
historical and cultural issues in due consideration and
meeting the local needs of research communities as a
way to give recognition to their contribution [8]. Similar
considerations are at play also in recent discussions con-
cerning next generation sequencing research. Most
experts agree that, in this domain, dedicated procedures
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should be in place to return incidental findings and re-
search results to participants [9–14]. However, there is
growing recognition of the possibility that return policies
could be explored and negotiated in a collective fashion
before sample, data and information are collected and
analyzed [15]. Partnership, in this case, would grant a
more active role to research subjects, patients and com-
munities as to their capacity to have a say on a number
of issues, ranging from protocol design to criteria for
recruitment, from feedback of research findings to direct
access to data and assessment of results.
For these strains of scholarship, the individual is no lon-
ger the only subject of moral rights – and thus the privi-
leged object of moral consideration. Groups, communities
and populations have cultural, identity-shaping interests
and should also be afforded appropriate moral consider-
ation. In this sense, valuing participation amounts at find-
ing ways to give a voice to those groups by involving them
in decisions concerning the collection, analysis and circu-
lation of their samples and data. Following this trend, a
whole constellation of values such as reciprocity, mutual-
ity, solidarity, universality and citizenry has taken center
stage, informing what has been described as a communi-
tarian turn in bioethics [5, 16].
Finally, transparency and accountability are often
considered as corollary values to direct engagement and
are routinely appealed to as ways to create and maintain
public trust in the scientific enterprise and its govern-
ance structures [17–26].
It should now be clear that participation and partner-
ship refer to a procedural ideal of direct engagement in
the activities that pertain health research and the devel-
opment of novel health paradigms. Advocates of part-
nership view direct engagement as a way to overcome
the alleged limitations of previously established ethical
frameworks and procedures focused almost exclusively
on respect for individual choice and autonomy in bio-
medical research and clinical practice.
Partnership, participation and precision medicine
Ideals of partnership, participation and the other core
values associated with them are routinely recalled in
discussions about an increasingly active role of research
participants in the development of personalized and
precision medicine [1, 27–30].
This feature should be greeted as potentially enriching
the scope of ethical discussion in this novel domain.
However, from these appeals, it is not entirely clear how
a national precision medicine cohort of one million indi-
viduals could integrate those ideals in a meaningful way.
For one thing, research participants will join the cohort
on a voluntary and, most probably, as individuals, that
is, not as members of a particular group. Moreover, even
if patient groups or any other types of communities
decided to join the cohort, their communitarian interests
would have to coexist with those of other (potentially
many) groups and communities that may decide to do
the same. In other words, the kind of communitarian
bonds that a participatory ethos is supposed to capture
and to promote are either yet to be formed or bound to
compete for the opportunity to have a say regarding the
governance of the cohort. This has so far surprisingly
escaped scholarly attention.
Normative emphasis on public participation and part-
nership at this early stage needs to come to terms with the
fact that a precision medicine cohort will initially be more
of a collection of individual data than a truly collective
entity. Given its large size, it will take time to assemble a
cohort in the first place, and, as a consequence, the com-
munity bonds that tie research participants together will
also only be forming gradually along the way. Moreover,
according to many, recruitment will likely continue even
after the threshold of one million participants is reached,
thus making the communitarian contours of the cohort
somewhat even more elusive to capture.
Obviously, the same holds for large-scale precision
medicine cohorts that, in the near future, will be consti-
tuted outside of the United States, in all other countries
that will endorse precision medicine as a promising
domain of innovation.
It follows that, as such cohorts get assembled, public
participation and collective engagement will not be as
meaningful to precision medicine research subjects as
they clearly are in the case of population genetics bio-
banks. Nevertheless, we think this should not entail a
fallback towards an individualistic framing of the ethical
stakes of precision medicine. As a precision medicine
cohort takes shape, research participants can still be
offered meaningful ways to fulfill the interests that par-
ticipation and partnership are supposed to protect. In
particular, perspective participants should be offered
ways to become members of communities and groups
that will form in the future, once the cohort acquires a
more definite shape. In other words, there can be good
ethical reasons to enable participants who enroll in pre-
cision medicine cohorts to become partners – even if we
look at them mainly as autonomous individuals. To this
aim, we propose a richer understanding of the idea of
autonomy that might bear on the process of enrolment
of research participants in precision medicine cohorts.
Autonomy revisited
In moral and political philosophy, the value of personal
autonomy expresses a concern for the idea “that people
should make their own life” [31]. Such concerns focus on
ideals of personal self-governance (or personal self-rule)
and freedom from external control and undue interference,
and points to the ethical worth of autonomous agents.
Blasimme and Vayena BMC Medical Ethics  (2016) 17:67 Page 3 of 8
To begin with, we can spell out our version of the
principle of respect for autonomy as respect for autono-
mous agents (or concern for autonomous lives), rather
than respect for autonomous action or choice. Focusing
on autonomous choice is at the core of informed consent
intended as a form of autonomous authorization (to
perform medical activities on one’s body in the context
of clinical care or research). This understanding of
autonomy has long been prominent in bioethics: it
stresses the value of being adequately informed, the im-
portance of the capacity to process this information, and
the absence of coercion or manipulation.
Indeed, valuing individual choice is of the utmost im-
portance in the context of clinical care and medical re-
search. However this understanding of autonomy may
prove too narrow. Following moral philosopher Joseph
Raz, we maintain that “one is autonomous if one deter-
mines the course of one’s life by oneself” [31]. Obviously,
this does not imply that one can gain full control of his or
her life without any influence from other people. What
this account of autonomy says is just that being coerced
into one’s own decisions or acting while being the object
of manipulation by others is not compatible with the ideal
of an autonomous life. As a consequence, third parties
have a prima facie duty not to unduly interfere with one’s
efforts at shaping the course of one’s life from a moral
point of view.
According to Raz, however, the absence of coercion
and manipulation is a necessary but not sufficient condi-
tion for an autonomous life absent “an adequate range
of options for [a person] to choose from” [31].4 This
further assumption follows from considering autonomy
as a guiding moral ideal for people’s life (as opposed to
considering it as an attribute of specific actions). This
has a consequence and a corollary. The consequence of
thinking that autonomy entails a meaningful set of
options is that it creates positive duties to actually pro-
vide those options. Obviously, this applies more directly
to those individuals or institutions that are capable of in-
fluencing the availability of moral options at a societal
level; but Raz does not exclude that each of us who is
committed to the value of autonomy also carries this
duty in one way or another. The corollary of that is
moral pluralism. What this expression designates is “the
view that there are various forms and styles of life which
exemplify different virtues and which are incompatible”
(in the sense that they cannot be pursued at the same
time by the same person) [31]. According to Raz, auton-
omy “requires that many morally acceptable, though
incompatible, forms of life be available to a person” [31],
and therefore it entails moral pluralism.5
For the purposes of our argument, we focus in particu-
lar on the most characteristic theoretical component of
a Razian understanding of autonomy, that is, the
importance of a meaningful range of worthwhile options.6
According to this criterion, having more options, per se,
does not enhance one’s capacity to be autonomous. For
example, having the option of doing something morally
bad (like stealing a drug), or being able to choose
between meaningless alternatives (e.g. choosing the color
of the pills we are asked to take if we are enrolled in a
clinical research study) cannot be said to enhance one’s
autonomy.7 A meaningful range of worthwhile options
in the context of health research has to do with morally
valuable interests that one has as a research participant.
Some of those interests are normally ensured at the
moment of ethical assessment of a given research project
by a research ethics committee (REC) or institutional
review board (IRB). This is the case, for instance, of in-
terests that pertain to physical integrity, like being ex-
posed to the minimum possible risk of physical harm, or
other valuable states, like avoiding both direct and indirect
privacy violations. But the attainment of other valuable
states of being cannot be delegated entirely to RECs or
IRBs. Those states do not pertain to the sphere of protec-
tion – like those just mentioned – but to the sphere of
freedom. While the former depend on the existence of
independent oversight mechanisms, the latter depend in-
stead on the availability of options to choose from. For in-
stance, being given the option of participating in decisions
about the governance of a research cohort, is typically as-
sumed to be a valuable thing by scholars who support a
participatory framing of research ethics. According to our
account of autonomous agency, it is relevant to personal
autonomy that one is offered the opportunity to be en-
gaged directly in decisions of this kind. Direct engagement
of this sort is valued by individuals as it affords the free-
dom to act in a certain way, namely as members of a self-
governing community that tries to attain what is of com-
mon interest. Having the option of assuming this role is
valuable for our Razian interpretation of autonomy.
Becoming partners
We are sympathetic to the general idea that progress in
precision medicine is predicated upon the recognition of
research participants as active partners. This ethical stance
is recurrently coupled with calls for supplementing the
ethical framework developed in the aftermath of the
Belmont Report and its emphasis on autonomous choice.
But the analytic point we would like to make here is
that the idea of partnership – and the concerns it sets
out to address – can find in our Razian understanding
of autonomy a valid normative ally. As we said above, a
major issue with the creation of large national precision
medicine cohorts is that participants do not initially con-
stitute a community of the kind that ideals of partner-
ship and participation are supposed to serve. It follows
that, if the kind of freedom those ideals promote is
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indeed ethically valuable, participants should be offered
meaningful options to become members of such a com-
munity, and thus to have access to those freedoms. We
reckon that valuing those freedoms entails making them
accessible to choice – which falls within our Razian
interpretation of autonomous agency.
But how does respect for autonomous agents play out in
practice? What does this principle require? And who
should be paying attention to the ethically relevant inter-
ests it promotes? We think the domain in which the
principle matters the most is in the design of participatory
governance structures for precision medicine cohorts.
More specifically, at the moment of enrollment, partic-
ipants should be presented with a detailed description of
the governance structure of the cohort, and of the op-
portunity to become actively involved with it. The latter
should include governance bodies in which scientists
and participants consider issues of common concern for
the management of the cohort. For instance, issues rela-
tive to the collection, use and distribution of the data, or
regarding the most appropriate informed consent mech-
anisms could be dealt with through direct engagement
of participants. Similarly, participatory governance can
promote the emergence of issues linked to the cultural
diversity that is likely to characterize a very large re-
search precision medicine cohort. This could also allow
participants to steer the research ambitions of the cohort
towards what are felt to be pressing public health con-
cerns. Upon enrollment, participants should thus be
made aware of the fact that – if interested – they can be
involved in the activities of such bodies, directly or, in
the case of large-scale cohorts, through mechanisms of
representation. This exceeds what is commonly taken
into account in informed consent forms and, as a matter
of fact, informed consent procedures are probably ill
suited for this kind of communication.
It is important, however, that those governance bodies –
their composition and agendas – remain as open as pos-
sible to be determined by participants themselves. Only in
this way will the existence of a participatory governance
structure enable participants to form the sort of commu-
nity bonds that ideals of partnership and engagement seek
to promote and protect. Assuming instead that those
bonds already exist and thus defining entirely in advance
the available modes of participation would actually restrict
the scope of ethical discussion to a limited set of pre-
determined options.
The governance of scientific research is certainly one of
the domains in which the value of participatory models is
easier to grasp [26]. The uptake of a participatory turn in
the governance of precision medicine thus represents a posi-
tive development. However, we should remain mindful of
the risk that participation and partnership end up assuming
an exclusively instrumental role of public legitimation
[21, 32–34]. In this respect, allowing for participants to have
some control on the scope and agenda of participatory gov-
ernance structures shows that appeals to participation are
more than just forms of political posturing.
As a matter of fact, assuming that people will be inter-
ested in active engagement in the development of
personalized medicine may unnecessarily set the bar too
high for the field. Recent episodes demonstrate that
patients can actually interpret engagement in ways that
can disenfranchise them more than making them com-
pliant partners of the research enterprise. For instance,
digital platforms such as PatientsLikeMe are often in-
voked as instantiations of the ideal of partnership and
direct engagement in the development of personalized
medicine [35]. Those platforms provide patients with the
opportunity to take direct control of their role as
research subjects, but they can also facilitate a form of
“patient-led disobedience” (for instance, protocol viola-
tions), instead of an endorsement of the predefined aims
of research [27]. Now, if we are serious about participa-
tion, we cannot fail to also recognize these more contro-
versial incarnations of the idea of direct engagement.
Using the principle of respect for autonomous agents as
a normative reference point, one is in a better position to
dissect the ethical value of any given form of engagement –
including those that point towards forms of “disobedience”
– as to their capacity to promote autonomy and expand
the scope of ethically valuable interests [36, 37].
Offering such options and opportunities to perspective
participants means recognizing their ethical importance
as autonomous agents, that is, agents that value having
those options and opportunities. Moreover, leaving it to
participants to define – as far as possible – the scope of
their engagement takes seriously the idea that public
participation is a way to explore what participants con-
sider common interests and common concerns. This can
also help balance relations of power and control between
research participants and scientific experts. Finally, pro-
viding opportunity of substantial direct engagement will
have a reputational payoff for publicly-run precision
medicine cohorts, thus helping to build public trust and
public confidence in those initiatives.
The fulfillment of a sense of partnership can certainly
constitute a stimulus for some to contribute to the de-
velopment of the field by donating samples and accept-
ing the collection of data about themselves. But most
importantly, being able to nurture a sense of partnership
and engagement, beyond the formalized routines of re-
search participation, expands the array of meaningful
choices available to perspective participants. According
to the account of autonomy that we have presented,
therefore, participants should be offered opportunities of
direct engagement as a matter of respect for them as
autonomous agents.
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Thus far, we have shown that the value of direct
engagement and participation can also be recognized if
we hold respect for autonomous agents as a guiding
principle in the development of medical paradigms
relying on extensive datasets.
We would like to conclude by stressing, once again,
that autonomy (properly understood) can actually serve
to address the concerns that have animated public
participation scholars for the last decade within the
field of genetics, genomics and personalized medicine.
A frequent worry with autonomy in this body of schol-
arship is that it manifests an individualistic under-
standing of moral life. We recognize the value of this
observation. However, the Razian account of autonomy
that we have advanced here clearly acknowledges that
“[p]eople’s individuality expresses itself in ways fash-
ioned by social practices, and through their ability and
inclination to engage in socially formed relations and
pursuits. Concern for individual freedom requires rec-
ognition that an important aspect of that ideal is the
freedom of people to belong to distinctive groups, with
their own beliefs and practices, and the ability of such
groups to prosper” [38].
Fostering community bonds, membership and engage-
ment is therefore more than merely compatible with hav-
ing autonomy as a reference ethical principle. As a matter
of fact, one of the reasons why autonomy is valuable is
precisely that it allows one to choose to belong to one of
those “distinctive groups”, and to engage directly with en-
suring its prosperity. Far from representing two alternative
ethical ideals, autonomy and partnership thus seem to
entertain a far more intricate conceptual relation than has
so far been imagined. With this paper, we attempted to
clarify some important aspects of that relation.
Conclusions
In current discussions and policy initiatives regarding the
development of personalized medicine, the existing ethical
frameworks – exemplified by the American Common
Rule – is frequently called into question. Appeals to direct
engagement and participation are frequent, but little the-
oretical work has been devoted to establishing their
normative foundations yet. In this paper we have set out
to fill this gap.
We have traced the emergence of precision medicine as
a novel paradigm in biomedical research and clinical prac-
tice. We explained that such transformation towards
increasingly personalized healthcare has proceeded along-
side an equally remarkable transformation in the domain
of ethics. With the growth of genetics and the advent of
high-throughput sequencing technologies, the established
ethical paradigm of the Belmont report and the Common
Rule – centered on the value of individual choice in both
research and clinical practice – started to appear
inadequate. We have shown that a participatory turn –
centered on the procedural notions of partnership and dir-
ect engagement – has taken shape to compensate for these
perceived shortcomings. We have discussed the theoretical
and practical relationships between the notion of partner-
ship and that of autonomy and argued for a Razian under-
standing of the latter. More specifically, we have proposed
a principle of respect for autonomous agents (or concern
for autonomous lives) emphasizing the availability of
meaningful arrays of choices for individuals enrolled in
precision medicine cohorts. We have shown that respect
for autonomous agents can vindicate the concerns raised
by participatory framings of research ethics, thus providing
a unified normative point of reference in this still emerging
area of biomedical innovation. Finally, we have maintained
that focusing on autonomy does not entail disregarding the
value of communitarian bonds and activities that link a
person to the communities she is a part of.
Endnotes
1Early articulations of the idea of partnership can also
be found in the work of philosophers like Hans Jonas, Jay
Katz and Paul Ramsey [39–42]. We thank one of the
reviewers for directing our attention on this body of work.
2In the remainder of the paper, we will use these
expressions interchangeably.
3For a more detailed account of the promise of precision
medicine and of its historical antecedents, see [43].
4The relevance of this account of autonomy for bioethics
has been shown in the context of Direct-to-consumer
(DTC) genomics and in the debate about the return of in-
cidental findings in whole genome sequencing, see [14, 44].
5Further conditions for Razian autonomy are the
development of what he calls inner capacities for
autonomous life, namely: the cognitive capacity to
process information, the emotional capacities to make
sense of the worth of our moral options, physical capaci-
ties to realize our autonomous life plans, and finally the
possession of character traits enabling the pursuit of an
autonomous life [31].
6As to the other two conditions for Razian auton-
omy (absence of coercion and manipulation and the
development of inner capacities to choose and pursue
autonomously chosen values and life plans), we think they
can be assumed to be implicit in the very ideal of direct
engagement.
7This entails that when we are offered opportunities to
choose, whether and how this contributes to our auton-
omy remains to be established. Discussing in greater
detail criteria of meaningfulness for options of autono-
mous choice in general falls beyond the scope of the
present paper. For a comprehensive philosophical ana-
lysis of the topic see [45], especially chapter 14. How-
ever, in the specific field of research ethics we can rely
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on moral commonsense and stipulate that options are
not relevant when they do not promote the interests and
expectations that research participants have as they
enroll in a study.
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